Delaunay et al. [1] presented the results of a retrospective study of 1826 cancer patients treated with immune-checkpoint inhibitors (ICIs). 3.5% of the patients developed interstitial lung diseases (ILDs). The mechanisms of this toxicity remain largely unknown [2]. The cohort was mainly composed of lung cancer patients (75%). This explains why a significant proportion of the patients (40%) with ILD had received thoracic radiotherapy. However, patients with ILD features within the initial volumes of radiotherapy were excluded from the study to dissociate cases related to radiation pneumonitis. This study is important and brings to the light key data regarding the emerging field of clinical management of adverse ICI events. Cases of radiation pneumonitis developed after concomitant checkpoint inhibitors and lung SBRT: a matter of concern? http://ow.ly/k78q30g1qDJ

中文翻译：

---

免疫疗法和肺毒性：伴随放疗的免疫检查点抑制剂会增加放射性肺炎的风险吗？

德劳内等人。[1] 介绍了一项对 1826 名接受免疫检查点抑制剂 (ICIs) 治疗的癌症患者的回顾性研究结果。3.5% 的患者出现间质性肺病 (ILD)。这种毒性的机制在很大程度上仍然未知[2]。该队列主要由肺癌患者（75%）组成。这就解释了为什么有很大比例的 ILD 患者 (40%) 接受了胸部放疗。然而，在初始放疗量内具有 ILD 特征的患者被排除在研究之外，以分离与放射性肺炎相关的病例。这项研究很重要，并揭示了有关 ICI 不良事件临床管理新兴领域的关键数据。伴随检查点抑制剂和肺 SBRT 后出现放射性肺炎病例：值得关注的问题？http://哦。